Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Research & Development (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Research & Development for 15 consecutive years, with $713.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 284.27% year-over-year to $713.2 million, compared with a TTM value of $1.0 billion through Dec 2025, up 158.38%, and an annual FY2025 reading of $1.0 billion, up 38.93% over the prior year.
  • Research & Development was $713.2 million for Q4 2025 at Neurocrine Biosciences, up from $250.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $713.2 million in Q4 2025 and bottomed at $5.0 million in Q1 2024.
  • Average Research & Development over 4 years is $148.0 million, with a median of $115.1 million recorded in 2021.
  • The sharpest move saw Research & Development tumbled 96.42% in 2024, then surged 650.0% in 2025.
  • Year by year, Research & Development stood at $92.7 million in 2021, then soared by 48.33% to $137.5 million in 2023, then surged by 34.98% to $185.6 million in 2024, then skyrocketed by 284.27% to $713.2 million in 2025.
  • Business Quant data shows Research & Development for NBIX at $713.2 million in Q4 2025, $250.0 million in Q3 2025, and $15.0 million in Q2 2025.